Penicillin V

Summary

Penicillin V (CHEMBL615) is an approved small molecule (ATC J01CE02); indicated across 10 conditions including bacterial infectious disease and infectious meningitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CE02
• Indications: 10 conditions
• Clinical trials: 15
• Chemistry: 350.4 Da · C16H18N2O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL615
Name	Penicillin V
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6869
ChEBI	CHEBI:27446
ATC	J01CE02
Molecular formula	C16H18N2O5S
Molecular weight	350.4
InChIKey	BPLBGHOLXOTWMN-MBNYWOFBSA-N

SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C

IUPAC name: (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

ChEBI definition: A penicillin compound having a 6β-(phenoxyacetyl)amino side-chain.

Also known as: Distaquaine v, Fenoximetilpenicilina, Penicillin phenoxymethyl, Penicillin v, Phenomycilline, Phenoxymethylpenicillin, Phenoxymethylpenicilline, Phenoxymethylpenicillinum, V-cillin, Vebecillin, Penicillin V, Phenoxymethyl penicillin

Parent form; salt/anhydrous children: CHEMBL1200852, CHEMBL1396177, CHEMBL2103963

Patent coverage: 3,544 distinct patent families (9,802 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Nuclear receptor ROR-gamma, Organic anion transporter 3.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
infectious meningitis	4	MONDO:0004796	EFO:0000584
bacterial infectious disease with sepsis	4	MONDO:0005229	EFO:0003033
arthritic joint disease	4	MONDO:0005578	EFO:0005856
scarlet fever	4	MONDO:0005952	EFO:0007477
bacterial endocarditis	4	MONDO:0006669	EFO:1000830

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
pneumonia	3	MONDO:0005249	EFO:0003106
rheumatic heart disease	2	MONDO:0006955	EFO:1001161

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE4	8
PHASE1	3
PHASE3	1
PHASE2	1
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04083417	PHASE4	RECRUITING	Sore Throat in Primary Care - a Comparison of Phenoxymethylpenicillin and No Antibiotic Treatment
NCT06295120	PHASE4	RECRUITING	The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark (CAP-D)
NCT07549594	PHASE4	NOT_YET_RECRUITING	Prophylaxis of Recurrent Erysipelas in Lower Limbs: compreSsion thErapy vs aNTibiotics and Compression Therapy.
NCT01368341	PHASE4	COMPLETED	Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice
NCT02185209	PHASE4	COMPLETED	Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics
NCT02712307	PHASE4	COMPLETED	Study of 5 and 10 Days Treatment With Penicillin Against Sore Throat Caused by Streptococci
NCT02922686	PHASE4	UNKNOWN	Penicillin for the Emergency Department Outpatient Treatment of CELLulitis
NCT04084106	PHASE4	COMPLETED	Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota
NCT03208361	PHASE3	TERMINATED	Efficacy of High Doses Penicillin V Versus High Doses Amoxicillin in the Treatment of Non-severe Pneumonia.
NCT05693545	PHASE2	ACTIVE_NOT_RECRUITING	GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial
NCT01499875	PHASE1	COMPLETED	A Pharmacokinetic and Pharmacodynamic Study of Phenoxymethylpenicillin for Children
NCT02188472	PHASE1	COMPLETED	Pentriox - Induction of Oxidative Stress
NCT03847610	PHASE1	COMPLETED	Minimally Invasive Sensing of Beta-lactam Antibiotics
NCT00823433	EARLY_PHASE1	TERMINATED	Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood
NCT03326661	Not specified	UNKNOWN	Peritonsillar Abscess: Aspiration Versus Tonsillectomy a Chaud

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).